1.87%
2.19%
-6.60%
-17.83%
-7.05%
-17.61%
28.52%
AI Spotlight on IQV
Company Description
IQVIA Holdings Inc.provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level.The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services.
The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services.It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies.The company has a strategic collaboration with HealthCore, Inc.
The company was formerly known as Quintiles IMS Holdings, Inc.and changed its name to IQVIA Holdings Inc.in November 2017.
IQVIA Holdings Inc.was founded in 1982 and is headquartered in Durham, North Carolina.
Market Data
| Last Price | 201.78 |
| Change Percentage | 1.87% |
| Open | 201.63 |
| Previous Close | 198.07 |
| Market Cap ( Millions) | 36623 |
| Volume | 2124596 |
| Year High | 261.73 |
| Year Low | 187.62 |
| M A 50 | 199.79 |
| M A 200 | 221.8 |
Financial Ratios
| FCF Yield | 5.35% |
| Dividend Yield | 0.00% |
| ROE | 21.50% |
| Debt / Equity | 196.64% |
| Net Debt / EBIDTA | 375.95% |
| Price To Book | 5.27 |
| Price Earnings Ratio | 26.15 |
| Price To FCF | 18.68 |
| Price To sales | 2.38 |
| EV / EBITDA | 15.11 |
News
- Jan -21 - IQVIA to Announce Fourth-Quarter and Full-Year 2024 Results on February 6, 2025
- Jan -15 - Will IQVIA (IQV) Beat Estimates Again in Its Next Earnings Report?
- Jan -13 - IQVIA and NVIDIA Collaborate to Transform Healthcare and Life Sciences Through Advanced Agentic AI Solutions
- Jan -03 - IQVIA Benefits From Global IT Infrastructure Amid Low Liquidity
- Dec -23 - IQVIA (IQV) Surges 3.0%: Is This an Indication of Further Gains?
- Dec -23 - Digital Health Tools are Expanding in Scope and Function to Aid Patient Diagnosis, Treatment and Monitoring, Says New Report from The IQVIA Institute
- Dec -19 - Iqvia initiated with an Overweight at Stephens
- Dec -12 - IQVIA Holdings: Share Price Disconnected From Growth Outlook
- Nov -28 - Why You Should Retain IQVIA Holdings Stock in Your Portfolio Now
- Nov -04 - Interpreting IQVIA (IQV) International Revenue Trends
- Nov -01 - IQVIA (IQV) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
- Oct -31 - IQVIA Holdings Inc. (IQV) Q3 2024 Earnings Call Transcript
- Oct -31 - IQVIA Earnings & Revenues Surpass Estimates in Q3, Increase Y/Y
- Oct -31 - IQVIA lowers annual revenue forecast amid trial delays
- Oct -31 - IQVIA Holdings (IQV) Q3 Earnings and Revenues Beat Estimates
- Oct -31 - IQVIA Reports Third-Quarter 2024 Results and Announces Investor Day
- Oct -28 - IQVIA Gears Up to Report Q3 Earnings: Here's What You Should Know
- Oct -28 - Seeking Clues to IQVIA (IQV) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
- Oct -15 - IQVIA to Announce Third-Quarter 2024 Results on October 31, 2024
- Oct -04 - Here's Why You Should Retain IQVIA Holdings Shares Now
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Research and Development Solutions
Expected Growth : 5.5 %
What the company do ?
Research and Development Solutions from IQVIA Holdings Inc. provide innovative clinical development, regulatory, and commercialization services to pharmaceutical and biotech companies.
Why we expect these perspectives ?
IQVIA Holdings Inc.'s Research and Development Solutions segment growth of 5.5% is driven by increasing demand for clinical trial outsourcing, adoption of digital technologies, and growing need for real-world evidence. Additionally, the company's investments in advanced analytics, artificial intelligence, and machine learning capabilities are enhancing its offerings, attracting new clients, and expanding existing relationships.
Segment n°2 -> Technology and Analytics Solutions
Expected Growth : 6.2 %
What the company do ?
Technology and Analytics Solutions from IQVIA Holdings Inc. provides advanced analytics, AI, and technology-enabled services to life sciences companies to improve clinical development, commercialization, and patient outcomes.
Why we expect these perspectives ?
IQVIA Holdings Inc.'s Technology and Analytics Solutions segment growth of 6.2% is driven by increasing demand for cloud-based solutions, artificial intelligence, and machine learning in the life sciences industry. Additionally, the need for real-world evidence, patient-centric approaches, and personalized medicine is fueling growth. Further, strategic partnerships, acquisitions, and investments in digital transformation are also contributing to the segment's growth.
Segment n°3 -> Contract Sales and Medical Solutions
Expected Growth : 5.8 %
What the company do ?
Contract Sales and Medical Solutions from IQVIA Holdings Inc. provides outsourced sales teams and medical affairs services to pharmaceutical and biotech companies.
Why we expect these perspectives ?
IQVIA Holdings Inc.'s Contract Sales and Medical Solutions segment growth of 5.8% is driven by increasing demand for outsourced commercialization services, expansion of existing client relationships, and growth in emerging markets. Additionally, investments in digital transformation and data analytics capabilities are enhancing the segment's competitiveness and driving revenue growth.
Iqvia Holdings Inc. Products
| Product Range | What is it ? |
|---|---|
| Real World Insights | IQVIA's Real World Insights provides real-world data and analytics to help life sciences companies understand patient outcomes, treatment patterns, and healthcare systems. |
| Clinical Development | IQVIA's Clinical Development services provide comprehensive clinical trial management, including site selection, patient recruitment, and data management. |
| Commercial Solutions | IQVIA's Commercial Solutions provide data-driven insights and analytics to help life sciences companies optimize their commercial strategies, including sales and marketing operations. |
| Research & Development Solutions | IQVIA's Research & Development Solutions provide integrated solutions for drug discovery, preclinical development, and clinical development. |
| Orchestrate | IQVIA's Orchestrate is a cloud-based platform that integrates data, analytics, and AI to help life sciences companies make informed decisions. |
| OCE (OneKey Customer Engagement) | IQVIA's OCE is a customer engagement platform that provides personalized, omnichannel experiences for healthcare professionals and patients. |
IQVIA Holdings Inc.'s Porter Forces
Threat Of Substitutes
IQVIA Holdings Inc. operates in a highly competitive industry, but the threat of substitutes is mitigated by the company's diversified portfolio of services and products, which reduces the likelihood of customers switching to alternative solutions.
Bargaining Power Of Customers
IQVIA Holdings Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's services and products are often critical to its customers' operations, making it difficult for customers to negotiate prices or terms.
Bargaining Power Of Suppliers
IQVIA Holdings Inc. relies on a network of suppliers for its operations, but the company's scale and diversified supply chain mitigate the bargaining power of individual suppliers. However, the company is still exposed to supplier concentration risks and potential disruptions to its supply chain.
Threat Of New Entrants
The threat of new entrants in the life sciences industry is low due to the high barriers to entry, including significant capital requirements, regulatory hurdles, and the need for specialized expertise. IQVIA Holdings Inc.'s established position and diversified portfolio of services and products also make it difficult for new entrants to gain traction.
Intensity Of Rivalry
The life sciences industry is highly competitive, with several large players competing for market share. IQVIA Holdings Inc. faces intense competition from established players and new entrants, which can lead to pricing pressure and reduced margins.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 69.27% |
| Debt Cost | 5.43% |
| Equity Weight | 30.73% |
| Equity Cost | 11.58% |
| WACC | 7.32% |
| Leverage | 225.46% |
IQVIA Holdings Inc. : Quality Control
IQVIA Holdings Inc. passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| MTD | Mettler-Toledo International Inc. engages in the manufacture and supply of precision instruments and services worldwide. It operates in five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and … |
| A | Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; … |
| IDXX | IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; … |
| TMO | Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences … |
| DHR | Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Mettler-Toledo
A-Score
1-Year Total Return ->
🥈
Thermo Fisher
A-Score
1-Year Total Return ->
🥉
Danaher
A-Score
1-Year Total Return ->
4
Agilent Technologies
A-Score
1-Year Total Return ->
5
IQVIA
A-Score
1-Year Total Return ->
6
